Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.

Autor: Badar T; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL. badar.talha@mayo.edu., Nanaa A; John H. Stroger, Jr. Hospital of Cook County, IL., Atallah E; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI., Shallis RM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT., Craver EC; Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL., Li Z; Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL., Goldberg AD; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, NY., Saliba AN; Division of Hematology, Mayo Clinic, Rochester, MN., Patel A; Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL., Bewersdorf JP; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, NY., Duvall A; Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL., Burkart M; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, Illinois., Bradshaw D; Division of Hematology and Oncology, Georgia Cancer Center, GA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, Illinois., Stahl M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Palmisiano N; Division of Hematology and Oncology, Jefferson University Hospital, Philadelphia, PA., Murthy GSG; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT., Kota V; Division of Hematology and Oncology, Georgia Cancer Center, GA., Patnaik MM; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, NY., Litzow MR; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, NY.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3533-3542. Date of Electronic Publication: 2024 Nov 01.

Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.

Autor: Rojek AE; Department of Medicine Section of Hematology/Oncology University of Chicago Chicago Illinois USA., McCormick BJ; Division of Hematology-Oncology Blood and Marrow Transplantation Program Mayo Clinic Jacksonville Florida USA., Cwykiel J; Department of Medicine Division of Hematology and Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago Illinois USA., Odetola O; Department of Medicine Division of Hematology and Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago Illinois USA., Abaza Y; Department of Medicine Division of Hematology and Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago Illinois USA., Nai N; Department of Internal Medicine University of New Mexico School of Medicine Albuquerque New Mexico USA., Foucar CE; Department of Internal Medicine Division of Hematology and Oncology University of New Mexico School of Medicine Albuquerque New Mexico USA., Achar RK; Department of Internal Medicine Section of Hematology Yale School of Medicine Yale University New Haven Connecticut USA., Shallis RM; Department of Internal Medicine Section of Hematology Yale School of Medicine Yale University New Haven Connecticut USA., Bradshaw D; Georgia Cancer Center Augusta University Augusta Georgia USA., Standridge M; Department of Internal Medicine Augusta University Medical College of Georgia Augusta Georgia USA., Kota V; Georgia Cancer Center Augusta University Augusta Georgia USA., Murthy GSG; Division of Hematology/Oncology Medical College of Wisconsin Milwaukee Wisconsin USA., Badar T; Division of Hematology-Oncology Blood and Marrow Transplantation Program Mayo Clinic Jacksonville Florida USA., Patel AA; Department of Medicine Section of Hematology/Oncology University of Chicago Chicago Illinois USA.

Publikováno v: EJHaem [EJHaem] 2024 Jul 24; Vol. 5 (4), pp. 728-737. Date of Electronic Publication: 2024 Jul 24 (Print Publication: 2024).

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Autor: Badar T; Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA. badar.talha@mayo.edu., Nanaa A; Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA., Atallah E; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Shallis RM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Guilherme SCC; Department of Internal Medicine, Mount Sinai Health System, New York, USA., Goldberg AD; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA., Saliba AN; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Patel A; Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA., Bewersdorf JP; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA., DuVall AS; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA., Bradshaw D; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, IL, USA., Murthy GSG; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Palmisiano N; Division of Hematology and Oncology, Jefferson University Hospital, Philadelphia, PA, USA., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Kota V; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA., Litzow MR; Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Feb 20; Vol. 14 (1), pp. 32. Date of Electronic Publication: 2024 Feb 20.

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.

Autor: Murthy GSG; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee. gmurthy@mcw.edu., Kim S; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee., Estrada-Merly N; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee., Abid MB; Divisions of Hematology/Oncology, and Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee., Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh., Assal A; Columbia University Irving Medical Center, Department of Medicine, Bone Marrow Transplant and Cell Therapy Program., Badar T; Mayo Clinic, Jacksonville, FL., Badawy SM; Division of Hematology, Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Department of Pediatrics, Northwestern University Feinberg School of Medicine., Ballen K; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Slyvester Comprehensive Cancer Center, Miami, FL., Cerny J; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA., Chhabra S; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee., DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital., Dholaria B; Vanderbilt University Medical Center, Nashville, TN., Perez MAD; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid., Farhan S; Henry Ford Health System Stem Cell Transplant and Cellular Therapy Program, Detroit, MI., Freytes CO; University of Texas Health Science Center at San Antonio, San Antonio, TX., Gale RP; Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London., Ganguly S; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS., Gupta V; MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Hamad N; St. Vincent Hospital, Darlinghurst, NSW., Hildebrandt GC; Markey Cancer Center, University of Kentucky, Lexington, KY., Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center, Tokyo., Jain T; John Hopkins University School of Medicine, Baltimore, MD., Jamy O; University of Alabama at Birmingham, Birmingham, AL., Juckett M; University of Minnesota Blood and Marrow Transplant Program - Adults., Kalaycio M; Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Krem MM; Kansas City VA Medical Center, Kansas City, MO., Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH., Litzow M; Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN., Munker R; Markey Cancer Center, University of Kentucky, Lexington, KY., Murthy HS; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center., Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL., Ortí G; Vall d'Hebron University Hospital, Barcelona., Patel SS; Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Van der Poel M; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Masstricht University Medical Center, Maastricht., Rizzieri DA; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigo., Solh M; The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA., Verdonck LF; Department of Hematology/Oncology, Isala, Clinic, Zwolle., Wirk B; Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania., Yared JA; Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD., Nakamura R; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Oran B; Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Scott B; Fred Hutchinson Cancer Research Center, Seattle, WA., Saber W; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee.

Publikováno v: Haematologica [Haematologica] 2023 Jul 01; Vol. 108 (7), pp. 1900-1908. Date of Electronic Publication: 2023 Jul 01.

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Autor: Badar T; Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL, USA. badar.talha@mayo.edu., Atallah E; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Shallis R; Yale University School of Medicine, New Haven, CT, USA., Saliba AN; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Patel A; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA., Bewersdorf JP; Yale University School of Medicine, New Haven, CT, USA., Grenet J; New York Presbyterian/Weill-Cornell Medical Center, New York, NY, USA., Stahl M; Department of Medical Oncology, Dana-Farber Institute, Boston, MA, USA., Duvall A; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA., Burkart M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Palmisiano N; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA., Bradshaw D; Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA., Kubiak M; Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA., Dinner S; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Goldberg AD; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Murthy GSG; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Kota V; Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA., Litzow MR; Yale University School of Medicine, New Haven, CT, USA.

Publikováno v: Leukemia [Leukemia] 2023 Apr; Vol. 37 (4), pp. 799-806. Date of Electronic Publication: 2023 Feb 18.